Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
129 shown of 8,678 total abstracts
  1. Abstract 50192026-04-04 · 15:15 CT · Arie Crown Theater
    OlympiA-417: Lynparza (olaparib) 3L+ in prostate
    S. Antonia, J. Cortes · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  2. Abstract 10662026-04-03 · 21:30 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-262
    S. Tolaney, S. Antonia, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  3. Abstract 98262026-04-05 · 18:00 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    J. Cortes, L. Paz-Ares, A. Spira, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumMelanoma📄🖼️
  4. Abstract 103452026-04-02 · 18:45 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-679 study)
    J. Cortes, S. Antonia · National Cancer Center Japan
    Clinical Science SymposiumMelanoma📄🖼️
  5. Abstract 60202026-04-04 · 18:00 CT · S406
    OlympiA-612: Lynparza (olaparib) adjuvant in ovarian
    R. Herbst, E. Winer, G. Curigliano · Massachusetts General Hospital
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  6. Abstract 98102026-04-03 · 16:00 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-148
    J. Brahmer, J. Cortes, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 91702026-04-04 · 13:00 CT · E450
    PACIFIC-494: Imfinzi (durvalumab) neoadjuvant in SCLC
    H. Borghaei, F. Andre, P. Schmid, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  8. Abstract 99652026-04-01 · 21:30 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    C. Saura, T. Mok, M. Krop · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 93792026-04-02 · 13:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-295
    S. Peters, A. Spira, L. Paz-Ares · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 13812026-04-03 · 18:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-157
    T. Mok, J. Brahmer, C. Robert · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  11. Abstract 48482026-04-04 · 19:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-20 study)
    C. Robert, T. Mok, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 15372026-04-02 · 21:30 CT · S406
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-960
    R. Herbst, C. Saura, S. Antonia, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  13. Abstract 40872026-04-03 · 21:15 CT · S406
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    H. Rugo, S. Peters · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 18042026-04-04 · 15:15 CT · S406
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-354
    H. Borghaei, S. Tolaney, M.C. Garassino, et al. · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  15. Abstract 11212026-04-03 · 18:15 CT · S100A
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    C. Saura, T. Mok, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  16. Abstract 12642026-04-05 · 20:00 CT · S406
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-979
    A. Spira, C. Saura · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  17. Abstract 96552026-04-02 · 18:30 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    E. Winer, M. Reck, S. Modi, et al. · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 67982026-04-04 · 13:45 CT · Hall B1
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-48
    S. Modi, M.C. Garassino · Dana-Farber Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 91742026-04-02 · 16:15 CT · S100A
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-441
    S. Peters, C. Robert · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 41502026-04-05 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-170 study)
    S. Tolaney, E. Winer, C. Saura · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 41702026-04-03 · 15:00 CT · S100A
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-569
    S. Modi, M.C. Garassino, S. Tolaney, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 45952026-04-02 · 14:30 CT · E450
    Long-term follow-up of Enhertu adjuvant for gastric: DESTINY-Breast-241
    J. Cortes, C. Robert, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  23. Abstract 58332026-04-01 · 19:30 CT · E450
    Quality of life outcomes with Lynparza in patients with ovarian
    S. Peters, L. Paz-Ares, F. Andre, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  24. Abstract 17302026-04-03 · 19:30 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    F. Andre, L. Paz-Ares, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  25. Abstract 92292026-04-04 · 13:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-272 study)
    S. Peters, T. Mok, C. Saura · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 47112026-04-02 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-249 study)
    E. Winer, L. Paz-Ares, T. Mok · Princess Margaret Cancer Centre
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  27. Abstract 18412026-04-03 · 18:15 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    F. Andre, H. Rugo, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  28. Abstract 19382026-04-05 · 13:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-282
    M. Reck, C. Saura, A. Spira, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  29. Abstract 94312026-04-04 · 13:15 CT · S100A
    FLAURA-57: Tagrisso (osimertinib) 2L in NSCLC
    E. Winer, F. Andre, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 104302026-04-05 · 14:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-366
    J. Brahmer, L. Paz-Ares · Dana-Farber Cancer Institute
    Clinical Science SymposiumMelanoma📄🖼️
  31. Abstract 94672026-04-05 · 21:00 CT · S406
    IMpower-233: Tecentriq (atezolizumab) 3L+ in NSCLC
    J. Brahmer, E. Winer, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 16002026-04-01 · 13:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-773 study)
    C. Robert, A. Spira · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  33. Abstract 90272026-04-04 · 14:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-291
    F. Andre, L. Paz-Ares, H. Rugo · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  34. Abstract 44232026-04-02 · 16:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-519
    T. Mok, G. Curigliano · Princess Margaret Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 43702026-04-01 · 16:45 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in HCC
    C. Robert, F. Andre · National Cancer Center Japan
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  36. Abstract 42452026-04-03 · 21:15 CT · Hall B1
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-375
    R. Herbst, M. Krop, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 11502026-04-03 · 18:30 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-365 study)
    A. Spira, M.C. Garassino · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  38. Abstract 40492026-04-04 · 20:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-302
    G. Curigliano, M. Reck, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  39. Abstract 91222026-04-04 · 19:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-649
    M. Reck, C. Robert, F. Andre · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 95472026-04-03 · 20:15 CT · S100A
    FLAURA-540: Tagrisso (osimertinib) 2L in NSCLC
    S. Tolaney, L. Paz-Ares, M. Reck, et al. · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 17002026-04-03 · 15:30 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    H. Borghaei, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  42. Abstract 17072026-04-03 · 15:30 CT · S100A
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    T. Mok, M. Krop · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  43. Abstract 94042026-04-01 · 16:00 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-374
    G. Curigliano, M. Krop, E. Winer, et al. · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 99262026-04-05 · 21:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-438 study)
    S. Antonia, T. Mok · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  45. Abstract 13252026-04-05 · 15:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-8 study)
    T. Mok, J. Brahmer, S. Peters, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  46. Abstract 45392026-04-03 · 19:00 CT · E450
    IMpower-769: Tecentriq (atezolizumab) maintenance in HCC
    S. Peters, N. Rizvi, S. Antonia, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  47. Abstract 10652026-04-04 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-190 study)
    N. Rizvi, H. Borghaei, S. Tolaney, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 16132026-04-02 · 19:30 CT · Arie Crown Theater
    IMpower-889: Tecentriq (atezolizumab) maintenance in TNBC
    J. Cortes, N. Rizvi, M. Reck · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  49. Abstract 55662026-04-01 · 19:45 CT · S406
    Long-term follow-up of Lynparza adjuvant for ovarian: OlympiA-514
    P. Schmid, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  50. Abstract 48302026-04-01 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-951 study)
    A. Spira, J. Brahmer, P. Schmid · Karolinska Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 91972026-04-02 · 14:45 CT · E450
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Tolaney, P. Schmid, J. Cortes · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  52. Abstract 48882026-04-01 · 13:15 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    C. Robert, P. Schmid, R. Herbst, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  53. Abstract 60942026-04-03 · 21:45 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-155
    H. Rugo, L. Paz-Ares, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  54. Abstract 49282026-04-04 · 15:00 CT · S406
    CheckMate-229: Opdivo (nivolumab) maintenance in HCC
    C. Robert, H. Borghaei, P. Schmid, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  55. Abstract 14182026-04-05 · 18:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-127 study)
    S. Peters, M.C. Garassino, R. Herbst, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  56. Abstract 62562026-04-01 · 14:45 CT · S100A
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-825
    R. Herbst, P. Schmid, C. Robert, et al. · Royal Marsden Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  57. Abstract 69192026-04-01 · 13:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    C. Robert, S. Antonia, S. Peters · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  58. Abstract 40582026-04-05 · 13:00 CT · E450
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-573
    M. Reck, H. Borghaei, C. Robert, et al. · Cleveland Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  59. Abstract 52692026-04-01 · 15:15 CT · E450
    Quality of life outcomes with Lynparza in patients with prostate
    C. Robert, P. Schmid · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  60. Abstract 96902026-04-03 · 20:15 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    F. Andre, R. Herbst, M.C. Garassino · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 48282026-04-03 · 14:00 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-963
    E. Winer, M. Krop, S. Antonia, et al. · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  62. Abstract 49722026-04-03 · 15:30 CT · Arie Crown Theater
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    L. Paz-Ares, C. Robert, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 18692026-04-01 · 19:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-222
    H. Borghaei, R. Herbst · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  64. Abstract 11122026-04-05 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-823
    P. Schmid, G. Curigliano, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  65. Abstract 16092026-04-03 · 19:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-42 study)
    F. Andre, L. Paz-Ares, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  66. Abstract 92892026-04-02 · 13:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-996 study)
    H. Borghaei, E. Winer, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 10802026-04-03 · 15:00 CT · E450
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-481
    S. Modi, M.C. Garassino · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  68. Abstract 14672026-04-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-250 study)
    L. Paz-Ares, F. Andre, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  69. Abstract 10792026-04-05 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-507 study)
    F. Andre, N. Rizvi, A. Spira, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  70. Abstract 12422026-04-01 · 18:45 CT · S100A
    MONALEESA-907: Kisqali (ribociclib) 2L in HR+ breast cancer
    H. Borghaei, C. Robert, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  71. Abstract 40222026-04-02 · 21:00 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    J. Brahmer, R. Herbst, C. Saura · Chinese University of Hong Kong
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  72. Abstract 49472026-04-01 · 18:15 CT · S100A
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-917
    M. Reck, M. Krop · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  73. Abstract 54622026-04-02 · 19:00 CT · S406
    OlympiA-931: Lynparza (olaparib) 2L in prostate
    M. Krop, M.C. Garassino, H. Borghaei · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  74. Abstract 16332026-04-04 · 21:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-348 study)
    N. Rizvi, C. Saura, A. Spira, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  75. Abstract 13892026-04-02 · 16:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-634 study)
    M. Krop, S. Modi, T. Mok, et al. · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  76. Abstract 98552026-04-04 · 14:45 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    H. Borghaei, H. Rugo, N. Rizvi · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 97072026-04-05 · 21:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-688
    N. Rizvi, L. Paz-Ares, P. Schmid · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  78. Abstract 10622026-04-03 · 14:15 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-694
    G. Curigliano, M. Reck, P. Schmid, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  79. Abstract 95262026-04-04 · 18:45 CT · Hall B1
    FLAURA-887: Tagrisso (osimertinib) 1L in NSCLC
    A. Spira, P. Schmid · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  80. Abstract 45282026-04-05 · 19:00 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    H. Borghaei, S. Modi · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  81. Abstract 57332026-04-02 · 18:15 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    M. Reck, N. Rizvi, E. Winer, et al. · Karolinska Institute
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  82. Abstract 15632026-04-02 · 13:15 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-676
    L. Paz-Ares, M. Krop, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  83. Abstract 11592026-04-05 · 13:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-655
    S. Modi, C. Saura, H. Rugo, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  84. Abstract 60682026-04-05 · 20:00 CT · Hall B1
    OlympiA-39: Lynparza (olaparib) 2L in ovarian
    H. Borghaei, C. Robert, S. Antonia, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  85. Abstract 94492026-04-01 · 15:15 CT · S100A
    IMpower-382: Tecentriq (atezolizumab) maintenance in NSCLC
    S. Tolaney, S. Antonia, M. Reck, et al. · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 14962026-04-05 · 16:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-107 study)
    E. Winer, L. Paz-Ares, C. Robert, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  87. Abstract 13692026-04-01 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-618 study)
    M. Reck, A. Spira, C. Saura, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  88. Abstract 19822026-04-05 · 14:30 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    H. Borghaei, C. Saura, N. Rizvi · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  89. Abstract 94042026-04-01 · 20:30 CT · Hall B1
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-25
    C. Robert, S. Modi · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 42062026-04-03 · 18:30 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-813
    S. Antonia, F. Andre · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  91. Abstract 51412026-04-04 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 3L+ for prostate: OlympiA-221
    C. Robert, L. Paz-Ares, F. Andre · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  92. Abstract 18692026-04-02 · 18:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-948
    M. Krop, S. Tolaney, H. Rugo, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  93. Abstract 95432026-04-01 · 13:45 CT · S100A
    CheckMate-110: Opdivo (nivolumab) 3L+ in metastatic melanoma
    S. Modi, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumMelanoma📄🖼️
  94. Abstract 49312026-04-02 · 15:30 CT · S100A
    EV-727: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    L. Paz-Ares, M. Reck · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  95. Abstract 11742026-04-01 · 14:00 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-474
    M.C. Garassino, S. Peters, F. Andre · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  96. Abstract 15312026-04-02 · 13:30 CT · E450
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    S. Tolaney, L. Paz-Ares · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  97. Abstract 95972026-04-01 · 13:00 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-493 study)
    M. Reck, R. Herbst, G. Curigliano · MD Anderson Cancer Center
    Clinical Science SymposiumMelanoma📄🖼️
  98. Abstract 13452026-04-05 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-520 study)
    L. Paz-Ares, A. Spira, S. Antonia · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  99. Abstract 11502026-04-04 · 13:45 CT · E450
    MONARCH-273: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    S. Modi, E. Winer · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  100. Abstract 46422026-04-04 · 14:30 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    A. Spira, M. Reck, R. Herbst, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  101. Abstract 50542026-04-02 · 21:15 CT · S406
    OlympiA-348: Lynparza (olaparib) neoadjuvant in prostate
    G. Curigliano, C. Robert, H. Rugo, et al. · Cleveland Clinic
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  102. Abstract 103732026-04-05 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-870 study)
    M.C. Garassino, M. Reck, R. Herbst, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumMelanoma📄🖼️
  103. Abstract 48282026-04-02 · 16:45 CT · E450
    ASCENT-916: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    S. Modi, H. Borghaei, F. Andre, et al. · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  104. Abstract 17862026-04-04 · 15:00 CT · E450
    PALOMA-411: Ibrance (palbociclib) 1L in HR+ breast cancer
    S. Antonia, M. Krop, J. Brahmer, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  105. Abstract 96612026-04-01 · 18:00 CT · Arie Crown Theater
    CheckMate-85: Opdivo (nivolumab) 3L+ in NSCLC
    H. Rugo, J. Brahmer, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 50202026-04-05 · 18:15 CT · S100A
    Long-term follow-up of Lynparza neoadjuvant for prostate: OlympiA-86
    J. Brahmer, L. Paz-Ares, H. Rugo, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  107. Abstract 46742026-04-05 · 20:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-700
    R. Herbst, S. Peters · Chinese University of Hong Kong
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  108. Abstract 40792026-04-01 · 13:15 CT · Hall B1
    ASCENT-49: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    H. Borghaei, J. Cortes, M. Reck, et al. · Stanford Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  109. Abstract 91642026-04-04 · 16:15 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-934
    J. Cortes, H. Rugo, M.C. Garassino · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 99552026-04-01 · 15:15 CT · S406
    CheckMate-301: Opdivo (nivolumab) 1L in metastatic melanoma
    S. Modi, P. Schmid, H. Borghaei, et al. · Institut Gustave Roussy
    Clinical Science SymposiumMelanoma📄🖼️
  111. Abstract 99772026-04-02 · 15:30 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-692
    R. Herbst, S. Peters, H. Borghaei · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 97002026-04-03 · 21:15 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    S. Tolaney, J. Brahmer, M.C. Garassino, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  113. Abstract 43752026-04-02 · 21:30 CT · E450
    EV-813: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    F. Andre, N. Rizvi, S. Antonia, et al. · Karolinska Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  114. Abstract 98282026-04-04 · 13:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-501
    N. Rizvi, S. Modi, A. Spira, et al. · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  115. Abstract 10052026-04-03 · 20:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-665
    H. Borghaei, N. Rizvi, A. Spira · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  116. Abstract 18632026-04-03 · 19:00 CT · S406
    MONALEESA-717: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Krop, M.C. Garassino, M. Reck, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  117. Abstract 53352026-04-02 · 19:30 CT · S100A
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-639
    R. Herbst, E. Winer, T. Mok, et al. · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  118. Abstract 46162026-04-02 · 18:00 CT · Hall B1
    IMpower-577: Tecentriq (atezolizumab) 3L+ in HCC
    E. Winer, S. Tolaney, R. Herbst · Princess Margaret Cancer Centre
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  119. Abstract 46912026-04-03 · 18:15 CT · S100A
    EV-118: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    S. Peters, M.C. Garassino, M. Krop, et al. · University of Chicago
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  120. Abstract 92372026-04-02 · 19:45 CT · Hall B1
    Long-term follow-up of Imfinzi maintenance for NSCLC: PACIFIC-15
    M. Krop, H. Borghaei, L. Paz-Ares · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  121. Abstract 14222026-04-01 · 18:45 CT · Hall B1
    MONARCH-768: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    E. Winer, F. Andre, M.C. Garassino · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  122. Abstract 44882026-04-04 · 16:00 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-487
    S. Modi, F. Andre · University of Chicago
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  123. Abstract 53752026-04-03 · 13:00 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in prostate
    M. Reck, M. Krop, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  124. Abstract 95432026-04-02 · 13:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    T. Mok, A. Spira, S. Modi · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 58592026-04-03 · 18:00 CT · Hall B1
    Long-term follow-up of Lynparza 2L for ovarian: OlympiA-477
    H. Borghaei, A. Spira · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  126. Abstract 19552026-04-05 · 13:30 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    C. Robert, J. Brahmer, G. Curigliano, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  127. Abstract 44362026-04-03 · 14:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-66 study)
    S. Peters, M. Reck, E. Winer, et al. · Cleveland Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  128. Abstract 41882026-04-05 · 19:30 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for gastric: DESTINY-Breast-930
    J. Brahmer, F. Andre, M.C. Garassino, et al. · National Cancer Center Japan
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  129. Abstract 13862026-04-04 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-423 study)
    C. Robert, S. Antonia, H. Rugo · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.